Pharma & Biotech
Exceptional track record - M&A.
View CDR's exceptional track record in IPOs and fundraisings.

$438 million acquisition by GE Healthcare (2006)

€50 million acquisition by Medigene (2006)

Acquisition of Combio (2004)

Acquisition of Link Pharmaceuticals (2006)

$104 million acquisition of CDS (2005)

£16 million acquisition by Oxford biomedica (2007)

$460 million Cambrex deal
$510 million Genentech deal
(2006)

Acquisition of 4AZA (2006)

$200 million acquisition of Sicomed (2005)

Merger of Strakan and Proskelia (2004)

Acquisition of MNL Pharma (2006)

£16.5 million acquisitions of Daniolabs and Dextra (2007)

€460 million acquisition of Eczacıbaşı (2007)





